阿里影業(01060.HK):授權寶與AGH訂立文娛作品合作框架協議
格隆匯4月1日丨阿里影業(01060.HK)宣佈,公司的合併附屬公司授權寶於2020年3月31日與AGH訂立文娛作品合作框架協議,合作期限自2020年4月1日起至2023年3月31日止。
根據文娛作品合作框架協議,授權寶或其任何關聯方與阿里巴巴集團之任何成員公司可(須受相關年度上限規限)就文娛作品訂立有關以下方面的具體協議:授出或轉讓該等權利;設計或營銷服務;IP衍生品委託生產服務;IP衍生品採購及代銷服務;廣告植入服務;居間服務;項目外包服務;票務服務;投資合作;代理運營服務;及技術及其他相關服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.